Has the time come for more personalised medicine in psychiatry?

Česká verzia

Authors: C. Höschl
Authors place of work: Ředitel: prof. MUDr. Cyril Höschl, DrSc., FRCPsych. ; Psychiatrické centrum, Praha
Published in the journal: Prakt. Lék. 2010; 90(8): 502-505
Category: Topic/News/Review

Summary

In psychiatry, personalised medicine in terms of treatment tailored to the individual patient can currently only be based on the knowledge of the mode of action of psychotropic drugs, their pharmacokinetics, and on predictive tests, e.g., QEEG methods. The use of molecular biology, genomics, and proteomics in psychiatry still lags behind other medical fields.

Key words:
personalised medicine, psychiatry, psychopharmacology.

Zdroje

1. Höschl, C. First-generation antipsychotics. In: Stolerman I.P. (ed.), Encyclopaedia of Psychopharmacology. Berlin-Heidelberg: Springer-Verlag, 2010.

2. Burns, M.J. The pharmacology and toxicology of atypical antipsychotic agents. J. Toxicol. Clin. Toxicol. 2001, 39(1), p. 1-14.

3. Horáček, J. a kol. Psychotické stavy v klinické praxi. Praha: Amepra, 2003.

4. Weiden, P.J. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J. Clin. Psychiatry 2007, 68, Suppl 4, p. 34-39.

5. Bareš, M., Brunovský, M., Kopeček, M et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: A pilot study. J. Psych. Res. 2007, 41(3-4), p. 319-325.